and MEK Targeted Therapies in Pediatric Central Nervous System Tumors

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Sep 9

PMID 36077798

Authors

Dario Talloa

Silvia Triarico

Pierpaolo Agresti

Stefano Mastrangelo

Giorgio Attina

Alberto Romano

Palma Maurizi

Antonio Ruggiero

Affiliations

Soon will be listed here.

Abstract

is a component of the MAPK and PI3K/AKT/mTOR pathways that play a crucial role in cellular proliferation, differentiation, migration, and angiogenesis. Pediatric central nervous system tumors very often show mutations of the MAPK pathway, as demonstrated by next-generation sequencing (NGS), which now has an increasing role in cancer diagnostics. The MAPK mutated pathway in pediatric CNS tumors is the target of numerous drugs, approved or under investigation in ongoing clinical trials. In this review, we describe the main aspects of MAPK and PI3K/AKT/mTOR signaling pathways, with a focus on the alterations commonly involved in tumorigenesis. Furthermore, we reported the main available data about current and MEK targeted therapies used in pediatric low-grade gliomas (pLLGs), pediatric high-grade gliomas (pHGGs), and other CNS tumors that often present or MEK mutations. Further molecular stratification and clinical trial design are required for the treatment of pediatric CNS tumors with and MEK inhibitors.

Citing Articles

The Role of Chronic Inflammation in Pediatric Cancer.

Mella C, Tsarouhas P, Brockwell M, Ball H Cancers (Basel). 2025; 17(1.

PMID: 39796780 PMC: 11719864. DOI: 10.3390/cancers17010154.

Multiparametric MRI along with machine learning predicts prognosis and treatment response in pediatric low-grade glioma.

Kazerooni A, Kraya A, Rathi K, Kim M, Vossough A, Khalili N Nat Commun. 2025; 16(1):340.

PMID: 39747214 PMC: 11697432. DOI: 10.1038/s41467-024-55659-z.

Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.

Wahid M, Khan M, Hussain J, Malik H, Umar S, Mughal S Medicine (Baltimore). 2024; 103(49):e40735.

PMID: 39654184 PMC: 11630983. DOI: 10.1097/MD.0000000000040735.

Dissecting the Natural Patterns of Progression and Senescence in Pediatric Low-Grade Glioma: From Cellular Mechanisms to Clinical Implications.

Gorodezki D, Schuhmann M, Ebinger M, Schittenhelm J Cells. 2024; 13(14.

PMID: 39056798 PMC: 11274692. DOI: 10.3390/cells13141215.

Noninvasive Molecular Subtyping of Pediatric Low-Grade Glioma with Self-Supervised Transfer Learning.

Tak D, Ye Z, Zapaischykova A, Zha Y, Boyd A, Vajapeyam S Radiol Artif Intell. 2024; 6(3):e230333.

PMID: 38446044 PMC: 11140508. DOI: 10.1148/ryai.230333.

References

Gibney G, Messina J, Fedorenko I, Sondak V, Smalley K . Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013; 10(7):390-9. PMC: 3983565. DOI: 10.1038/nrclinonc.2013.83. View

Gaillard P, Appeldoorn C, Dorland R, van Kregten J, Manca F, Vugts D . Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One. 2014; 9(1):e82331. PMC: 3885379. DOI: 10.1371/journal.pone.0082331. View

McCubrey J, Steelman L, Chappell W, Abrams S, Wong E, Chang F . Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2006; 1773(8):1263-84. PMC: 2696318. DOI: 10.1016/j.bbamcr.2006.10.001. View

Maraka S, Janku F . BRAF alterations in primary brain tumors. Discov Med. 2018; 26(141):51-60. View

Rodriguez-Viciana P, Warne P, Dhand R, Vanhaesebroeck B, Gout I, Fry M . Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994; 370(6490):527-32. DOI: 10.1038/370527a0. View

Davies K, Maxwell R, Seljeskog E, Sung J . Pleomorphic xanthoastrocytoma--report of four cases, with MRI scan appearances and literature review. Br J Neurosurg. 1994; 8(6):681-9. DOI: 10.3109/02688699409101181. View

Srinivasa K, Cross K, Dahiya S . Alteration in Central and Peripheral Nervous System Tumors. Front Oncol. 2020; 10:574974. PMC: 7523461. DOI: 10.3389/fonc.2020.574974. View

Bouche V, Aldegheri G, Donofrio C, Fioravanti A, Roberts-Thomson S, Fox S . BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?. Front Oncol. 2021; 11:772052. PMC: 8595319. DOI: 10.3389/fonc.2021.772052. View

Polivka Jr J, Janku F . Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2013; 142(2):164-75. DOI: 10.1016/j.pharmthera.2013.12.004. View

10.

Manning B, Cantley L . Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003; 28(11):573-6. DOI: 10.1016/j.tibs.2003.09.003. View

11.

Behling F, Barrantes-Freer A, Skardelly M, Nieser M, Christians A, Stockhammer F . Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol. 2016; 11(1):55. PMC: 4924254. DOI: 10.1186/s13000-016-0506-2. View

12.

Cheng Y, Tian H . Current Development Status of MEK Inhibitors. Molecules. 2017; 22(10). PMC: 6151813. DOI: 10.3390/molecules22101551. View

13.

Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X . TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006; 126(5):955-68. DOI: 10.1016/j.cell.2006.06.055. View

14.

Santarpia L, Lippman S, El-Naggar A . Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16(1):103-19. PMC: 3457779. DOI: 10.1517/14728222.2011.645805. View

15.

Niault T, Baccarini M . Targets of Raf in tumorigenesis. Carcinogenesis. 2010; 31(7):1165-74. DOI: 10.1093/carcin/bgp337. View

16.

Lockman P, Mumper R, Khan M, Allen D . Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm. 2002; 28(1):1-13. DOI: 10.1081/ddc-120001481. View

17.

Zhang J, Wu G, Miller C, Tatevossian R, Dalton J, Tang B . Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013; 45(6):602-12. PMC: 3727232. DOI: 10.1038/ng.2611. View

18.

Rankin A, Johnson A, Roos A, Kannan G, Knipstein J, Britt N . Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers. Oncologist. 2020; 26(1):e153-e163. PMC: 7794197. DOI: 10.1002/ONCO.13519. View

19.

Yao Z, Seger R . The ERK signaling cascade--views from different subcellular compartments. Biofactors. 2009; 35(5):407-16. DOI: 10.1002/biof.52. View

20.

Chang F, Steelman L, Lee J, Shelton J, Navolanic P, Blalock W . Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003; 17(7):1263-93. DOI: 10.1038/sj.leu.2402945. View